ASX:CSL News 16 January 2026 - 7 February 2026

CSL shares closed Friday at A$181.42, up 1.13%, as investors await half-year results and an interim dividend announcement on Feb 11. The RBA meets Feb 2–3, with its decision expected to influence rate expectations and market sentiment. The ASX 200 fell 0.7%, pressured by mining stocks, while healthcare outperformed.

CSL shares closed up 1.1% at A$181.42 Friday after hitting A$184.41 earlier in the session. Vanguard raised its voting power in CSL to 6.0% from about 5.0%, according to a substantial holding notice. Investors await CSL’s half-year results and interim dividend announcement on Feb. 11.

CSL shares closed down 0.44% at A$179.40 in Sydney on Thursday. Vanguard increased its stake in CSL to 6%, acquiring nearly 5 million additional shares. Deutsche Bank will take over as depositary bank for CSL’s U.S. ADR program from Jan. 27. CSL’s half-year results and interim dividend update are due in February.

CSL shares closed up 0.7% at A$179.62 on Friday ahead of the Australia Day market holiday. The ASX cash market will be shut Monday and reopen Tuesday. CSL will report half-year results and announce an interim dividend on Feb. 11. The S&P/ASX 200 rose 0.13% to 8,860.1, while traders increased bets on a February rate hike.

CSL shares rose 0.1% to A$176.70 Tuesday after RBC Capital Markets upgraded the stock, despite the ASX 200 falling 0.66%. The move follows a 36% drop in CSL’s share price over the past year and comes ahead of its Feb. 11 half-year results. RBC cited competition and weak flu vaccine demand as near-term risks. CSL last cut its 2026 revenue and profit growth forecasts in October and delayed its Seqirus spin-off.

CSL shares closed at A$175.53 on Friday, up 0.14%, with about 1 million shares traded. The company will report half-year results and set its interim dividend on Feb. 11. Investors remain focused on the Seqirus vaccines outlook after CSL cut its FY26 growth guidance in October. Shares are scheduled to trade ex-dividend on March 10.

CSL (ASX:CSL) closed Friday at A$175.53, up 0.14%, after filing in the U.S. to register up to 100 million American depositary shares. Around 1.07 million shares changed hands, with prices ranging from A$174.35 to A$176.07. Investors await CSL’s half-year results on Feb. 11 for updates on plasma therapies and vaccines.